BridgeBio clinical trials

The registry lists 50 studies whose lead sponsor is BridgeBio or one of 13 companies grouped under it. 13 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 14, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 50.

• Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsRecruitingNCT06625775Phase 1

  Sponsor listed in the registry: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · First submitted after TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) left BridgeBio

• Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic HypoparathyroidismRecruitingNCT07805356Phase 3

  Sponsor listed in the registry: Calcilytix Therapeutics, Inc., a BridgeBio company

• Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung CancerRecruitingNCT06343402Phase 1

  Sponsor listed in the registry: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · First submitted before TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) left BridgeBio

• Open-Label, Long-Term, Extension Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitationNCT07393373Phase 2

  Sponsor listed in the registry: QED Therapeutics, a BridgeBio company

• To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)Not yet recruitingNCT07116473Phase 3

  Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio

• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRecruitingNCT06563895Phase 3

  Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio

• Cardiac Magnetic Resonance and Echocardiography Study With AcoramidisRecruitingNCT07695701Phase 4

  Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio

• Prospective Clinical Assessment Study in Children With HypochondroplasiaRecruitingNCT06410976

  Sponsor listed in the registry: QED Therapeutics, a BridgeBio company

• An Interventional Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitationNCT06873035Phase 2/3

  Sponsor listed in the registry: QED Therapeutics, a BridgeBio company

• Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)RecruitingNCT07169279Phase 2

  Sponsor listed in the registry: QED Therapeutics, a BridgeBio company

• BBO-11818 in Adult Subjects With KRAS Mutant CancerRecruitingNCT06917079Phase 1

  Sponsor listed in the registry: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · First submitted after TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) left BridgeBio

• Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)RecruitingNCT07080385Phase 2/3

  Sponsor listed in the registry: Calcilytix Therapeutics, Inc., a BridgeBio company

• Extension Study of Infigratinib in Children With Achondroplasia (ACH)Enrolling by invitationNCT05145010Phase 2

  Sponsor listed in the registry: QED Therapeutics, a BridgeBio company

• Open-Label Study of AG10 in Patients With CardiomyopathyTerminatedNCT03536767Phase 2

  Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio

• Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)Active, not recruitingNCT05775848Phase 3

  Sponsor listed in the registry: ML Bio Solutions, Inc. · First submitted after ML Bio Solutions, Inc. became part of BridgeBio

• Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1Active, not recruitingNCT05680818Phase 3

  Sponsor listed in the registry: Calcilytix Therapeutics, Inc., a BridgeBio company

• Study of BBP-418 in Patients With LGMD2IActive, not recruitingNCT04800874Phase 2

  Sponsor listed in the registry: ML Bio Solutions, Inc. · First submitted after ML Bio Solutions, Inc. became part of BridgeBio

• Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9Active, not recruitingNCT07678775Phase 3

  Sponsor listed in the registry: ML Bio Solutions, Inc. · First submitted after ML Bio Solutions, Inc. became part of BridgeBio

• ADH1 and ADH2 Disease Monitoring Study (DMS)Active, not recruitingNCT05227287

  Sponsor listed in the registry: Calcilytix Therapeutics, Inc., a BridgeBio company

• Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)CompletedNCT04035811

  Sponsor listed in the registry: QED Therapeutics, a BridgeBio company

• A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With AchondroplasiaCompletedNCT06164951Phase 3

  Sponsor listed in the registry: QED Therapeutics, a BridgeBio company

• A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)Active, not recruitingNCT04783181Phase 1/2

  Sponsor listed in the registry: Adrenas Therapeutics Inc

• Study of Infigratinib in Children With AchondroplasiaCompletedNCT04265651Phase 2

  Sponsor listed in the registry: QED Therapeutics, a BridgeBio company

• Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR ParticipantsActive, not recruitingNCT04988386Phase 3

  Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio

• SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C MutationTerminatedNCT05480865Phase 1

  Sponsor listed in the registry: Navire Pharma Inc., a BridgeBio company

• First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid TumorsTerminatedNCT04528836Phase 1

  Sponsor listed in the registry: Navire Pharma Inc., a BridgeBio company

• SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS MutationTerminatedNCT05375084Phase 1

  Sponsor listed in the registry: Navire Pharma Inc., a BridgeBio company

• Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1CompletedNCT04581629Phase 2

  Sponsor listed in the registry: Calcilytix Therapeutics, Inc., a BridgeBio company

• Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)WithdrawnNCT04882735Phase 3

  Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio

• A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])CompletedNCT05101902

  Sponsor listed in the registry: Adrenas Therapeutics Inc

• Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid PolyneurophathyWithdrawnNCT04418024Phase 3

  Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio

• A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy SubjectsCompletedNCT04769479Phase 1

  Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio

• Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10CompletedNCT03294707Phase 1

  Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio

• Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid CardiomyopathyCompletedNCT03860935Phase 3

  Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio

• Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/TranslocationsTerminatedNCT03773302Phase 3

  Sponsor listed in the registry: QED Therapeutics, Inc.

• Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic AlterationsTerminatedNCT04197986Phase 3

  Sponsor listed in the registry: QED Therapeutics, Inc.

• A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic AcidemiaTerminatedNCT04836494Phase 1

  Sponsor listed in the registry: CoA Therapeutics, Inc., a BridgeBio company

• Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type ACompletedNCT02629393Phase 2/3

  Sponsor listed in the registry: Origin Biosciences

• Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMPCompletedNCT02047461Phase 2

  Sponsor listed in the registry: Origin Biosciences

• A Phase II, Single Arm Study of BGJ398 in Patients With Advanced CholangiocarcinomaTerminatedNCT02150967Phase 2

  Sponsor listed in the registry: QED Therapeutics, Inc.

• Biomarker Development in LGMD2iCompletedNCT04202627

  Sponsor listed in the registry: ML Bio Solutions, Inc. · First submitted after ML Bio Solutions, Inc. became part of BridgeBio

• Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)CompletedNCT05143190Phase 2

  Sponsor listed in the registry: Phoenix Tissue Repair, Inc.

• Study of AG10 in Amyloid CardiomyopathyCompletedNCT03458130Phase 2

  Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio

• First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene MutationsTerminatedNCT04409145Phase 1/2

  Sponsor listed in the registry: Venthera, Inc., a BridgeBio company

• A Study of BBP-711 (ORF-229) in Healthy Adult VolunteersCompletedNCT04876924Phase 1

  Sponsor listed in the registry: Cantero Therapeutics, a BridgeBio company

• A Study of PTR-01 in Recessive Dystrophic Epidermolysis BullosaCompletedNCT04599881Phase 2

  Sponsor listed in the registry: Phoenix Tissue Repair, Inc.

• A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)CompletedNCT03752905Phase 1/2

  Sponsor listed in the registry: Phoenix Tissue Repair, Inc.

• Phase 1 Single Dose Study of ALXN1101 in Healthy VolunteersCompletedNCT01894165Phase 1

  Sponsor listed in the registry: Origin Biosciences

• A Retrospective, Observational, Noninterventional Data Collection Study for Patients With Molybdenum Cofactor Deficiency Who Have Been Previously Treated With Cyclic Pyranopterin Monophosphate (cPMP)CompletedNCT01640717

  Sponsor listed in the registry: Origin Biosciences

• A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase DeficienciesCompletedNCT01735188

  Sponsor listed in the registry: Origin Biosciences